Nonetheless, EGFR inhibitors, including the EGFR-blocking antibody cetuximab or EGFR kinase inhibitors, have had disappointing outcomes in the clinic (17, 27), suggesting alternative mechanisms through which EGFR promotes or sustains the progression of these cancers. The gene discussed is EGFR; the disease is cancer.